Immuneering Corp (IMRX)

Currency in USD
4.960
-0.090(-1.78%)
Closed·
4.922-0.038(-0.77%)
·
IMRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.9055.110
52 wk Range
1.10010.080
Key Statistics
Prev. Close
5.05
Open
5.05
Day's Range
4.905-5.11
52 wk Range
1.1-10.08
Volume
929.96K
Average Volume (3m)
1.73M
1-Year Change
210%
Book Value / Share
3.38
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IMRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
17.000
Upside
+242.74%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Immuneering Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Compare IMRX to Peers and Sector

Metrics to compare
IMRX
Peers
Sector
Relationship
P/E Ratio
−5.7x−6.0x−0.5x
PEG Ratio
−0.16−0.190.00
Price/Book
1.5x7.1x2.6x
Price / LTM Sales
-13.6x3.1x
Upside (Analyst Target)
187.1%62.5%54.6%
Fair Value Upside
Unlock7.2%7.6%Unlock

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 17.000
(+242.74% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy12.00+141.94%13.00Maintain09/03/2026
Oppenheimer
Buy30.00+504.84%-Maintain06/03/2026
Leerink Partners
Buy15.00+202.42%-New Coverage31/10/2025
Mizuho
Buy12.00+141.94%10.00Maintain29/10/2025
Oppenheimer
Buy30.00+504.84%21.00Maintain25/09/2025

Earnings

Latest Release
Mar 06, 2026
EPS / Forecast
-0.18 / -0.3119
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IMRX Income Statement

People Also Watch

5.360
SLS
-0.19%
4.510
NUVB
+1.58%
59.600
IDR
+1.02%
21.460
SLRS
+2.88%
4.88
RCKT
+3.17%

FAQ

What Is the Immuneering (IMRX) Stock Price Today?

The Immuneering stock price today is 4.960 USD.

What Stock Exchange Does Immuneering Trade On?

Immuneering is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Immuneering?

The stock symbol for Immuneering is "IMRX."

What Is the Immuneering Market Cap?

As of today, Immuneering market cap is 319.390M USD.

What Is Immuneering's Earnings Per Share (TTM)?

The Immuneering EPS (TTM) is -1.273.

When Is the Next Immuneering Earnings Date?

Immuneering will release its next earnings report on 12/05/2026.

From a Technical Analysis Perspective, Is IMRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Immuneering Stock Split?

Immuneering has split 0 times.

How Many Employees Does Immuneering Have?

Immuneering has 53 employees.

What is the current trading status of Immuneering (IMRX)?

As of 16/03/2026, Immuneering (IMRX) is trading at a price of 4.960 USD, with a previous close of 5.050 USD. The stock has fluctuated within a day range of 4.905 USD to 5.110 USD, while its 52-week range spans from 1.100 USD to 10.080 USD.

What Is Immuneering (IMRX) Price Target According to Analysts?

The average 12-month price target for Immuneering is 17.000 USD, with a high estimate of 30 USD and a low estimate of 11 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +242.74% Upside potential.

What Is the IMRX After Hours Price?

IMRX's last after hours stock price is 4.922 USD, the stock has decreased by -0.038, or -0.770%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.